Aspect Biosystems and Novo Nordisk announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity.
Under the terms of the agreement, Novo Nordisk will receive an exclusive, worldwide licence to use Aspect
